Patient enrollment is now complete in a Phase 2 trial that’s assessing the safety and efficacy of oral risvodetinib, being developed by Inhibikase Therapeutics to slow or stop the progression of Parkinson’s disease. The 201 trial (NCT05424276) has enrolled 120 participants across 32 sites in the U.S.,…
Scientists at the University of Dundee in Scotland said they have uncovered the mechanisms behind the activation of the PINK1 protein, an enzyme that protects the brain against nerve cell degeneration and the development of Parkinson’s disease. They discovered how PINK1, which detects damage in mitochondria — the cell’s…
A new ultra-high-performance brain imaging PET system called NeuroEXPLORER allows for the direct imaging of deep regions of the brain, that is, the brain nuclei, and may help diagnose and advance treatments for brain diseases, including Parkinson’s disease. The research was presented at the 2024 Society of Nuclear…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $595,000 grant to Alchemab Therapeutics to advance research on the therapeutic effects of an antibody targeting the prostaglandin pathway in people with Parkinson’s disease. The grant comes from the foundation’s Parkinson’s Disease Therapeutics Pipeline Program,…
Researchers at the Icahn School of Medicine at Mount Sinai have identified LRRK2 gene mutations as a common element in both inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, and Parkinson’s disease. The study also identified genes involved in inflammation…
Support networks are important for people with Parkinson’s disease, and patients in rural areas don’t always have access to information that would help improve their lives, Central Michigan University researchers said. The researchers are wrapping up a year-long project studying whether creating support networks in underserved U.S. rural communities…
Physical exercise may reduce the risk of developing Parkinson’s disease, as well as effectively control patients’ symptoms, according to a review analysis by researchers in Europe. Moreover, some studies suggest that exercise might be a potential disease-modifying treatment, working to slow disease progression and stabilizing, or even reducing, the…
The European Inventor Award 2024 has named as finalists a French husband-and-wife team of scientists who developed a dosing pump that allows for direct delivery of dopamine to the brain in people with Parkinson’s disease. The use of dopamine is expected to help reduce symptoms and so-called off…
Serina Therapeutics has partnered with Enable Injections to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease, in combination with the enFuse wearable delivery system. EnFuse is designed to allow patients to self-administer SER-252 subcutaneously (under the skin) in a faster, simpler, and more…
An oral spray was safe and efficient at delivering apomorphine to people with Parkinson’s disease, a study found. A subcutaneous injection formulation of apomorphine, sold as Apokyn, is approved in the U.S. to treat off episodes — periods in which symptoms return between doses of levodopa treatment — in…
Get regular updates to your inbox.
